It’s Time to
Build in Bio
Our ability to engineer biology is fundamentally transforming how we diagnose, treat, and manage disease. Modern tools like CRISPR and gene circuitry enable us to program biology with greater precision and sophistication. The explosion of “programmable medicines” (in the form of genes, cells, microbes, and even mobile apps and software that can improve our health itself) are today leading us closer than ever before to that holy grail of medicine, the cure.
Because these new medicines are engineered systems and programmable in nature, drug discovery and development is becoming an engineered, iterative process. We can now move from designing a molecule for one specific target to designing a platform on which many future medicines can be built. And the modular aspect of these medicines mean that new applications will be easier to build, reusing and repurposing common components like Lego blocks: Once we learn how to deliver a gene to a specific cell in a given disease, it’s significantly more likely we will be able to deliver a different gene to a different cell for another disease.
Biology is incredibly complex —maybe even beyond the ability of the human mind to fully comprehend. AI-powered platforms have the potential to connect dots that have before looked like noise; to generate new discoveries; even to change the nature of discovery itself. This will drive both new therapies and next-generation diagnostics that give us the ability to detect diseases like cancer earlier and earlier, perhaps even stopping disease before it begins..
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Themes in Bio
Science-native SaaS tools are modernizing how medicines are discovered, developed, and distributed.
Bio Eats World
Our top-ranked podcast exploring the intersection of technology, biology, and the transformation of healthcare.
Building in Bio
A new generation of founders is building a new generation of bio companies.
Journal Club: Remodeling oncogenic transcriptomes
Unexpected results and translational implications from a recent paper, in one of our Journal Club podcast episodes.
AI in Bio + Health
A universe of new therapies, next-gen diagnostics, and provider tools is on the horizon.
the Field of Immunotherapies
Immuno-oncology and current challenges in drug targeting, explained.
AI and Actionable Drug Insights with Daphne Koller
Hear about how AI can enable new models of discovery in biology, in this episode of Bio Eats World.
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.
As we strive to find and support the most ambitious life sciences founders, we also work to connect these founders with exceptional advisors who have traveled the journey before.
The world is amidst an AI-driven industrial revolution. Whether we let it improve the health of Americans is up to how we regulate it. There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare.
AI will have the greatest impact on life sciences and health when it can succeed at specialist tasks like diagnoses and medical procedures.